Last reviewed · How we verify

NCT03026517

Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated Melanoma

Completed Phase 1 Last updated 21 January 2025
What this trial tests

Phase 1 trial testing Dabrafenib in Melanoma in 18 participants. Completed in 21 January 2025.

Timeline
1 January 2017
Primary endpoint
21 January 2025
21 January 2025

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment18
Start date1 January 2017
Primary completion21 January 2025
Estimated completion21 January 2025
Sites3 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to test whether it is safe to give phenformin with the standard drug combination of one of 3 FDA-approved combinations of BRAF inhibitor + MEK inhibitor which are standard treatments for patients with metastatic melanoma whose melanoma has a mutation in a gene called BRAF.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The future of cancer immunotherapy: microenvironment-targeting combinations.
    Murciano-Goroff YR, Warner AB, Wolchok JD. · · 2020 · cited 554× · PMID 32467593 · DOI 10.1038/s41422-020-0337-2
  2. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
    Zappasodi R, Merghoub T, Wolchok JD. · · 2018 · cited 386× · PMID 29634946 · DOI 10.1016/j.ccell.2018.03.005
  3. Altered metabolism in cancer: insights into energy pathways and therapeutic targets.
    Tufail M, Jiang CH, Li N. · · 2024 · cited 265× · PMID 39294640 · DOI 10.1186/s12943-024-02119-3
  4. Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
    Xu Y, Xue D, Bankhead A, Neamati N. · · 2020 · cited 127× · PMID 33103432 · DOI 10.1021/acs.jmedchem.0c01013
  5. Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy.
    Wolpaw AJ, Dang CV. · · 2018 · cited 121× · PMID 29229182 · DOI 10.1016/j.tcb.2017.11.006
  6. Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia.
    de Beauchamp L, Himonas E, Helgason GV. · · 2022 · cited 119× · PMID 34561557 · DOI 10.1038/s41375-021-01416-w
  7. Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy.
    Li J, Eu JQ, Kong LR, Wang L, et al · · 2020 · cited 99× · PMID 33092283 · DOI 10.3390/molecules25204831
  8. Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors.
    Lee M, Hirpara JL, Eu JQ, Sethi G, et al · · 2019 · cited 96× · PMID 30594485 · DOI 10.1016/j.redox.2018.101073

Verify or expand the search:

Other trials of Dabrafenib

Trials testing the same drug.

Other recruiting trials for Melanoma

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03026517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing